MedTrace Logo

Comparison of Outcomes Between Topical Minoxidil Versus Oral Minoxidil for the Treatment of Androgenetic Alopecia

NCT07273799 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2025-12-10

No results posted yet for this study

Summary

To compare the outcome of topical minoxidil 5% spray versus oral minoxidil 2.5 mg tablet for the treatment of androgenetic alopecia in males and females. Outcomes include efficacy of the treatment, measured by reduction in hair shedding, improvement in hair density and new hair growth as assessed by physican and patient assessment as well as safety, defined as incidence and severity of adverse events over a treatment period of 6 months

Conditions

  • Androgenic Alopecia

Interventions

DRUG

Minoxidil 5 % Topical Spray

Topical spray on hairs

DRUG

minoxidil

Oral minoxidil 2.5mg

DRUG

Placebo Spray

placebo spray

DRUG

Placebo Tablet or Capsule

Placebo tablet

Sponsors & Collaborators

  • Sheikh Zayed Federal Postgraduate Medical Institute

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-20
Primary Completion
2026-05-01
Completion
2026-06-01

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07273799 on ClinicalTrials.gov